http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김형민,이승구,송석환,정양국,이주엽,하난경,손일남,박일중,Kim, Hyoung-Min,Rhee, Seung-Koo,Song, Seok-Whan,Chung, Yang-Guk,Lee, Joo-Yup,Ha, Nan-Kyoung,Son, Il-Nam,Park, Il-Jung 대한미세수술학회 2006 Archives of reconstructive microsurgery Vol.15 No.2
With advances in techniques and instrumentation, the primary concern of microsurgeons has shifted from flap anatomy and survival toward flap refinement and donor-site function and aesthetics because flap survival rates have risen 96 percent. However, the problem still remains on regard that most flap has disadvantages that flap itself is too bulky or leaves unaesthetic scar to the donor site. These problems can be solved by using adipofascial flap instead of fasciocutaneous flap. The adipofascial flap not only has minimal donor site morbidity, but also can be retained thin. It seems that its advantages can be applied on soft tissue defect of exposed body part.
슬관절염에서 폴리뉴클레오티드나트륨의 반복치료 안전성 및 유효성
김완호,송영선,류호광,박종훈,김국진,손일남 대한임상통증학회 2023 Clinical Pain Vol.22 No.2
Objective: The objective of this study is to assess the efficacy and safety of repeated sodium polynucleotide (ConjuranⓇ) treatments in patients with knee osteoarthritis. Methods: The study was conducted by retrospectively examining 45 patients who repeated the treatment course of 5 injections of ConjuranⓇ twice within 6 months. For each course, pain reduction by the change of 100-mm Weight-Bearing-Pain Visual-Analog-Scale was compared with before administration until 6 months after administration. Improvement by Clinical Global Impression (CGI) and Patient Global Impression (PGI) were also investigated, as well as adverse reactions. Results: Pain analysis after administration of ConjuranⓇ confirmed that VAS decreased by 51.6% until 6 months (p<0.001), and after that the effect was lost and was repeat for the 2nd course. In the 2nd, VAS continued to decrease by 58.7% compared to before the 1st course (p<0.001). Analysis of CGI, 88.9% of patients improved after the 1st and 84.4% of patients improved after the 2nd. In the PGI results, symptoms improved in 86.7% of patients after the 1st and 82.2% after the 2nd. No significant adverse event was reported. Conclusion: The safety and efficacy results of patients receiving ConjuranⓇ for 2nd treatment courses were similar to those for 1st treatment course. In addition, the effect lasts for up to 6 months after administration, and the pain reduction effect is lost thereafter, so it is recommended to apply it at 6-month intervals if additional treatment is needed. ConjuranⓇ is an intra-articular injection that is effective in reducing knee pain and can be used repeatedly without adverse reactions.